multiple walls of patent applications covering the space of pregnancy immunology, it will possess sufficient freedom to operate in its product development, as well as generate possible licensing revenues from others seeking to enter the space.
and various agents to alter pathological conditions in the maternal immune system.
OCEANSIDE, CA--(Marketwired - April 24, 2017) - Therapeutic Solutions International, Inc.'s (OTC PINK: TSOI) subsidiary, OmniBiome, Inc., announced today the successful development of an oral microbiome probiotic intended to treat periodontal disease delivered by an oral appliance.
OmniBiome’s main focus will be on developing Dx / Rx products & services for pregnancy-associated conditions or diseases.
The word microbiome is defined as the collection of microbes or microorganisms that inhabit an environment, creating a sort of “mini-ecosystem”. Our human microbiome is made up of communities of symbiotic, commensal and pathogenic bacteria (along with fungi and viruses) all of which call our bodies home.
OmniBiome, Inc. is the world’s first company focused on therapeutic / Rx approaches to either utilize or intervene with the systemic effects of the vaginal, lactal-duct and oral microbiomes for improving maternal healthcare and resulting birth outcomes.
Therapeutic Solutions International, Inc. has licensed certain intellectual property to OmniBiome.